Thanks, yes - I saw that presentation at the 2020 CMRC meeting, so that was my introduction to her work.@Hilda Bastian just wondering if you considered asking Dr Nina Muirhead?
Thanks, yes - I saw that presentation at the 2020 CMRC meeting, so that was my introduction to her work.@Hilda Bastian just wondering if you considered asking Dr Nina Muirhead?
Yes. This is a political problem of why standards are not being followed for ME, and are indeed actively being diluted and discarded. It isn't a technical problem with the normal standards, that everybody else has to follow.To be honest a fair amount of Cochrane's own videos/blogs etc on stats/bias etc isn't bad. It just doesn't seem to apply to any papers on ME.
This....blinding is important in treatment trials, and that even if a treatment can't be blinded, we cannot just ignore the problem altogether. We need find some other way to minimise these sources of bias or alternatively, assess their impact on the outcomes.
"in the later stages of treatment patients are encouraged to increase their activity (which must ultimately be the aim of any treatment)"
Wessely, David, Butler, & Chalder – 1990
Nothing in the criteria suggests the need for people with proven knowledge, skills and experience with in depth reviewing of clinical trials.Consumers, as defined by Cochrane, could be people with personal experience of ME/CFS or carers for them. We agreed on these criteria for these positions:
We aimed for geographic and gender diversity in the team.
- Different experiences/beliefs about exercise and ME/CFS that reflect something of the range of people's experiences, and ideally different experiences of ME/CFS;
- A history of interest in research on ME/CFS;
- Experience working in groups producing work with people of different views, shown by having previously been involved in science-related groups or a background of working in a professional environment where processes involved collaboration;
- An understanding of the implications of being involved in an ME/CFS controversy, demonstrated by having been public about their experience with ME/CFS, and using social media; and
- One with a background of ME/CFS community advocacy and one without, and at least one woman with ME/CFS, as ME/CFS affects predominantly women.
After the report of 20 March 2020, the pandemic hit its stride, slowing people down generally, and pretty much everything that wasn't pandemic response.
How on earth does being a 'non activist' patient specially qualify someone for this task?
What particular contribution is a non-activist expected to make to the detailed examination of data that could not be fulfilled by an expert patient who also happens to have taken part in some activism?
I am lost. Even if my assumptions about an open application process were wrong, and that's not how Cochrane works, surely they look for appropriate knowledge and expertise in their review authors.
But please, to help us all, to relieve the distress of those who feel accused, and to clear yourself of accusations of buying into the harassment narrative, please can you either be more specific about what you are referring to, or alternatively, retract the accusations of 'pounding'.
It would be good to clear the air on these issues so we can all return to focusing on the important and valuable role the IAG, and the good people on it, can play in the review, and the part we can play in feeding into that process when invited, our comments on the protocol and anything we are asked to participate in.
I am seeing a process that almost could not have been designed better to make people with ME/CFS familiar with the issues with GET be frustrated and despairing. I have no doubt that our expressions of frustration will be turned back on us by some, to suggest that we aren't grateful when people try to help us, that we are a very difficult community and that is why so few people want to be associated with ME/CFS. But, a straight-forward evidence review that was staffed by qualified unbiased people would not be causing these problems.
I hope Hilda that you will understand what I am saying here. It's a car crash in motion. I will try to look away soon, but I'm concerned about the damage to the ME/CFS community that will be left at the end. Please just start again, aiming to make the review simpler and more robust.
Thanks, @Trish - sorry, I hadn't seen this had been posted, when I clicked post reply on the post I'd been drafting.I agree that the information we have about the patient on the review panel tells us nothing about her particular suitability for the role. I think an explanation of this surprising appointment lies in the criteria spelled out in Hilda's report:
https://community.cochrane.org/orga...ofile-reviews-pilot/cochrane-exercise-and#Two
Nothing in the criteria suggests the need for people with proven knowledge, skills and experience with in depth reviewing of clinical trials.
I apologise if this has already been answered, but I would like to know from @Hilda Bastian
- who came up with these criteria,
- what role people selected to fit these criteria are expected to play in the technical process of reviewing research, including data analysis, and understanding and being able to contribute to decisions on what to conclude from the evidence including being able to explain why some data is unfit for purpose (eg the Chalder Fatigue Questionnaire).
There is only one of the above criteria which hints at a useful background, but it is so vague as to be meaningless:
'A history of interest in research on ME/CFS'
if you go to 'search forum' and select 'search tags' then enter 'muirhead' you should find most of them here.I would be interested to have links provided for the above mentioned videos. I did a quick google and nothing came up that was related.
But what really concerns me is that Hilda says that she found Kay online;
The project manager for the update is Rachel Marshall, from the EMD in London.
One exception to these processes for this review will be a brief public consultation of the peer-reviewed protocol. A preprint of the manuscript will be released, and a consultation process will be planned by the IAG. As well as submitting written comments, there will be opportunities for people to comment using less formal communication methods.
Thanks for your post. Two was the maximum for consumers on this group for this process, with this timeline - but there is the IAG too, there will be peer reviewers, and there'll be other ways to contribute. And it's a Cochrane review, so if there's new evidence etc, it can kick into life again - at that point, if the intensity of conflict around this review has lessened and the review is normalized - which I believe is an achievable goal - then timelines and dealing with public pressure and expectations are removed from the situation, and major barriers/deterrents to being involved would be lifted.Would it be possible to have a few different patients with ME/CFS involved, to represent a diverse range of experiences? Specifically, someone who is on the severe end? It may be hard to find someone who is well enough, but this seems very important. Many of us do not recognize the lives or understand the issues important to those affected either a lot more or a lot less severely. This seems fair enough given the dramatic differences in the life of eg someone who can do part time work vs someone who is bedbound or housebound.
there will be peer reviewers,
I agree with just about all of that - w00t!!! The only part I don't agree with is the peer review part: given the history here, the new editors are obviously keen to send out something they feel confident in, and I think that's totally understandable. It's not a reason to feel like this means it's basically done and dusted. (But you don't need to see the next report to know that recommendations of peer reviewers can be made now to cochrane.iag@gmail.com - I'll take them here, but there's less risk of falling through cracks if there's an email.)One thing I think is important is this
It is really important that patients get to comment on the protocol as that is at the heart of what the review will say and whether it will be any good. I am worried about the brief comment as patients need time to digests if brief is say just a week that is insufficient time for a good response given peoples illness. I don't see why it can't be done at the same time as peer review.
I also think it is really important that comments are taken into account and coherent reasons (not just we will have to differ here like happended with comments on the previous cochrane review) should be given for the major criticisms. Also I'm concerned that putting a peer reviewed protocol out for further comment could lead to difficulties in getting changes as I can see comments 'but peer reviewers said it was fine' even though peer review is a really poor process (as people don't have time for detailed analysis).
So it would be good to have the full process layed out now in terms of proposed time scales and any back and forth that will be expected with the IAG, peer reviewers, the patient community etc. Lets have a process defined (it can change if necessary) rather than doing it in an adhoc manner.
Yes.Will some peer reviewers be drawn from the patient community?
Will some peer reviewers be drawn from the patient community?
Yes.
(or both...) -- Thanks, Adrian. Very important point.but may allow those whose health is not up to doing a full review (or who have prefered to stay anonymous
Yeah, you can do a lot when it's not a pandemic, in an organization going into pandemic response mode, and people suddenly home-schooling left, right, and center (which I can attest even hit grandmothers pretty hard). (As I said, there'll be recommendations in the end about options, timelines, etc.)What bothers me is that Hilda was searching online for candidates and then appointing them rather than running an open (and perferably transparant) process. If we compare this to say how the PSP recruited people by setting up an initial small committee (including the CMRC PAG representatives and @MEMarge nominated from here) and using that to advertise and operate a recuritment process. That got good candidates and this is at the heart of progressing.
Isn't this meant to be a template process for other reviews and including 'consumers' and hence it is worth reflecting on the process, how it is run, how it would be reproduced and how it compares to other processes that seek to get patients involved (such as the PSP).
Updates on this overall recruitment process could have been given over time as they were happening. Things like opening up for applications with a close date; what was being looked for for applicants (reflecting the range of skills and knowledge that would be valued). This didn't seem to happen (although I admit I've been very busy doing other stuff so it may have slipped by).
And I noticed on Hilda's report that
So I would have hoped that a project manager from Cochrane would have pushed for a better process.
Yeah, you can do a lot when it's not a pandemic, in an organization going into pandemic response mode, and people suddenly home-schooling left, right, and center (which I can attest even hit grandmothers pretty hard). (As I said, there'll be recommendations in the end about options, timelines, etc.)